Andrea Charles | 11/04/2012
With budget cuts hitting hard in the R&D field, it is imperative to validate the worth of predictive methods internally as they continue to facilitate the reduction in late stage drug attrition. But the challenges remain: how do we cost-effectively develop and implement these in-vitro methods as accurately and as early in the drug discovery process as possible?Jorrit J. Hornberg, PhD Head of Section In Vitro Studies, Exploratory Toxicology at Lundbeck, speaks to Andrea Charles fro...
To continue reading this story Click Here
RECOMMENDED
Upcoming Events
DigIT Pharma AI Commercial Excellence & Health 2025
September 01 - 03, 2025
Palace Hotel Berlin, Germany
Register Now |
View Agenda |
Learn More
AI for Pharma & Healthcare
23 - 25 September, 2025
Amsterdam
Register Now |
View Agenda |
Learn More